CoChat

Semaglutide in Obesity: Unmet Needs in Men

Open access
Jensterle, Mojca, Rizzo, Manfredi, Janež, Andrej · 2023 · Diabetes Therapy
Cited by 36

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Gender-specific issues in weight management with semaglutide need to be addressed to maximize the benefits of this agent to patients. Global average data suggest that the prevalence of male obesity is increasing and that its prevalence in some regions of Western Europe, Japan, China, Korea and USA is higher than that of female obesity [1]. However, men appear reluctant to engage in weight loss intervention programs despite verified established links between obesity and health-related diseases [2]. This reticence may reflect a general failure to recognize gender issues in weight management. A novel second-generation anti-obesity pharmacotherapy strategy against obesity represents a considerable advance in the efficacy of obesity management programs, as well as a significant change in the treatment of obesity [3]. The Semaglutide Treatment Effect in People with Obesity (STEP) Phase 3a clinical development program evaluated the safety and efficacy of the first second-generation medication, namely semaglutide, administered subcutaneously once weekly, for weight management in adults with obesity or overweight with at least one weight-related comorbidity [4–7]. STEP 2 enrolled patients with overweight or obesity with type 2 diabetes (T2D), while the other STEP studies (STEP 1, 3 and 4) enrolled patients with overweight or obesity, without T2D [4–7]. In STEP 4, patients who reached and tolerated a maintenance dose of semaglutide 2.4 mg during a 20-week run-in period were randomized at week 20 to continue semaglutide or switch to placebo [7]. M. Jensterle A. Janež (&) Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia e-mail: andrej.janez@kclj.si

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-022-01360-7

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 9

  1. Dombrowski SU, McDonald M, van der Pol M, Grindle M, et al. Game of Stones: feasibility randomised controlled trial of how to engage men with obesity in text message and incentive interventions for weight loss. BMJ Open. 2020;10(2): e032653. · DOI
  2. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–25. · DOI · Paper page
  3. Overgaard RV, Petri KCC, Jacobsen LV, Jensen CB. Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis. Clin Pharmacokinet. 2016;55:1413–22. · DOI · Paper page
  4. Kerstetter KA, Ballis MA, Duffin-Lutgen S, Carr AE, Behrens AM, Kippin TE. Sex differences in selecting between food and cocaine reinforcement are mediated by estrogen. Neuropsychopharmacology. 2012;37:2605–14. · DOI
  5. Park MI, Camilleri M. Gastric motor and sensory functions in obesity. Obes Res. 2005;13:491–500. · DOI · Paper page
  6. Kim DY, Camilleri M, Murray JA, Stephens DA, Levine JA, Burton DD. Is there a role for gastric accommodation and satiety in asymptomatic obese people? Obes Res. 2020;9:655–61. · DOI
  7. Camilleri M, Iturrino J, Bharucha AE, et al. Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol Motil. 2012;24:1076-e562. · DOI · Paper page
  8. Kapitza C, Lynge J, Düring M, Jensen C. Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects. Diabetologia. 2012;55:S1–538.
  9. Janez A, Muzurovic E, Stoian AP, et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol. 2022;365:8–18. · DOI

Cited by

See all 36

Metadata

Authors
Jensterle, M., Rizzo, M., & Janež, A.
Venue
Diabetes Therapy
Published
2023-01-07
Volume
14
Issue
3
Pages
461-465
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4313656426
Cited by
36
References
13
FWCI
4.61
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide in Obesity: Unmet Needs in Men. https://app.cochat.ai/papers/10.1007/s13300-022-01360-7
The paper
Jensterle, M., Rizzo, M., & Janež, A. (2023). Semaglutide in Obesity: Unmet Needs in Men. Diabetes Therapy. https://doi.org/10.1007/s13300-022-01360-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.